All In Biotech

Drug Trial Radar · NCT06710899

Vitamin C and Hiprex in rUTI

Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Aug 2027

Study completion Jan 2028

Sponsor

Lead sponsor
University Hospitals of North Midlands NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women

Conditions

  • Urinary Tract Infections

Interventions

  • Methenamine Hippurate 1g BDDrug

    Methenamine Hippurate 1g BD for 6 months

  • Methenamine Hippurate 1g BD + Vitamin C 1g BDDrug

    Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of UTIsTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals of North Midlands NHS Trust

    Stoke-on-Trent, Staffordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.